This systematic review synthesizes evidence from recent randomized controlled trials (RCTs) to determine the relative efficacy and safety of SGLT2 inhibitors versus GLP-1 RAs in reducing cardiovascular and renal outcomes in T2DM patients. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.